Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

In this study, researchers found that a combination of celery and candlenut extracts significantly increased hair length in male Wistar rats, while hair weight increased with either extract alone or combined, and hair thickness was most improved with candlenut extract alone.

In a case study, Ayurvedic treatments of leech therapy and topical application of Jayapala beej churna reportedly addressed dosha imbalances associated with Indralupta (Alopecia areata), resulting in new hair growth after several sessions.

In this review, the authors noted that while baricitinib, a treatment for refractory rheumatoid arthritis and severe alopecia areata, shows promising efficacy, it may pose risks of serious infections and malignancy due to immune downregulation.

This review explores the role of JAG1 in disease treatment, highlighting the need for effective methods to deliver JAG1 in its bound form to activate NOTCH signaling for therapeutic applications in craniofacial bone loss and myocardial infarction.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

Low-dose oral minoxidil is safe for treating hair loss, especially in women, with side effects stopping after use ends.

In this single case study, Ayurvedic treatments using Madhuka taila nasya and Japaakusumadi lepa were reported to benefit a patient with premature hair graying, suggesting a potential safe and effective alternative to conventional methods.

This review article compiles extensive information on Tridax procumbens, an Ayurvedic herb, detailing its traditional uses, chemical makeup, and various pharmacological properties, including its roles in wound healing and as an antimicrobial agent.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This study found that JAK1 and JAK2 inhibitors increase β-catenin activity in human hair follicle cells, suggesting an additional therapeutic mechanism for treating severe alopecia areata.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

This review discusses the phytochemical and pharmacological properties of Jatropha dioica, highlighting its potential uses in traditional medicine and the need for more scientific validation of its effects.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This report suggests that a Unani formulation, jawarish Falafali, effectively reduced symptoms and TSH levels in a 35-year-old woman with hypothyroidism over two months, while T3 and T4 levels remained normal.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

This study found that a lotion containing specific plant extracts significantly increased the number of anagen hairs and the anagen/telogen ratio in subjects with androgenetic alopecia after three months of use.

This review discusses the FDA-approved JAK inhibitor baricitinib as a treatment for alopecia areata, highlighting its dosing regimen, clinical challenges, and the need for additional safety data while exploring the potential of other topical and sublingual JAK inhibitors under investigation.

This case report details a 37-year-old woman with alopecia areata who experienced significant hair regrowth after psychological stress-triggered hair loss, following treatment with topical corticosteroids and tofacitinib.

This study suggests that particulate matter can induce inflammation in human outer root sheath cells, potentially affecting hair growth, through oxidative stress-dependent MAPK and JAK-STAT signaling pathways.

This article reviews the mode of action, efficacy, and safety of Janus kinase inhibitors in autoimmune dermatological conditions but reports no new clinical results.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

In this source, a case of a female patient with indralupta (alopecia areata) was successfully treated using Ayurvedic methods, specifically jaluaka, haridra, and nimbalepa, suggesting an effective alternative to corticosteroids, which have harmful side effects and are unsuitable for long-term use.

This review discusses recent findings on the efficacy of JAK inhibitors for treating alopecia areata, highlighting their role in reversing hair loss by targeting the JAK-STAT signaling pathway, though questions about their effectiveness and safety remain.